Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre- or poststeroid pulse treatment

Abstract

PurposeTo investigate whether serum levels of soluble Fas (sFas) and interleukin-6 (IL-6) could function as an index of the efficacy of steroid pulse treatment, we examined the serum level of these proteins before and after steroid pulse treatment in thyroid-associated ophthalmopathy patients.MethodsWe gathered the blood of thyroid-associated ophthalmopathy patients before or after steroid pulse treatment, obtained serum with a centrifuge, and measured the serum levels of sFas and IL-6 by enzyme-linked immunosorbent assay (ELISA).ResultsThere was no difference in serum IL-6 value between pre- and poststeroid pulse treatment. Serum sFas value was significantly decreased in both pre- and poststeroid pulse treatment. Furthermore, there was a recognizable improvement in the degree of the extraocular muscle thickening after treatment in cases in whom the serum sFas value was lower than 3 ng/ml prior to the beginning of the therapy. In patients who had a serum sFas value of more than 3 ng/ml, there was no improvement in the degree of thickening of the extraocular muscle.ConclusionsSerum level of sFas is an accurate index of the outcome of steroid pulse treatment in thyroid-associated ophthalmopathy and may become a useful index to gauge the status of convalescence.

Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women

“…The exact mechanism attempting to explain how cellular constituents make their way from the apoptotic cell into serum still remains unclear (10). Several studies have measured circulating levels of sFas and sFasL under various disease states, such as atherosclerosis (12), coronary artery disease (13,14), thyroid-associated ophthalmopathy (15), testicular toxicity (16), renal failure (17), liver disease (18), and cancer (19,20). Cytochrome c has been suggested as a possible serum marker of mitochondria-mediated apoptosis (10,21).…”

Δράση Προγεσταγόνων Διαφορετικής Προέλευσης Ορμονικής Θεραπείας Χαμηλής Δόσης Στην Αθηρωματική Διαδικασία Διαμέσου Της Αποπτωτικής Ομοιοστασίας

“…Aξθεηέο κειέηεο έρνπλ κεηξήζεη θπθινθνξνχληα επίπεδα sFas θαη sFasL ζε δηάθνξεο παζνινγηθέο θαηαζηάζεηο, φπσο αζεξνζθιήξπλζε 17 , ζηεθαληαία λφζν 82,83 , νθζαικνπάζεηα ζρεηηδφκελε κε ζπξενεηδνπάζεηα 84 , θαξκαθεπηηθή ηνμηθφηεηα ζηνπο φξρεηο 85 , λεθξηθή αλεπάξθεηα 86 , επαηηθή λφζν 87 θαη θαθνήζεηεο [88][89][90] . Σα απμεκέλα επίπεδα sFas ζην πιάζκα ζπλδένληαη κε ηα θαξδηαγγεηαθά λνζήκαηα θαη κπνξνχλ λα έρνπλ πξνγλσζηηθή αμία γηα θαξδηαγγεηαθά ζπκβάκαηα ζε λεθξνπαζείο 16 .…”